Mutational profiling of colorectal cancers with microsatellite instability

Elaine I. Lin, Li Hui Tseng, Christopher Gocke, Stacy Reil, Dung Le, Nilofer Azad, James Eshleman

Research output: Contribution to journalArticle

Abstract

Microsatellite instability (MSI) is caused by defective mismatch repair in 15-20% of colorectal cancers (CRCs). Higher mutation loads in tumors with mismatch repair deficiency can predict response to pembrolizumab, an anti-programmed death 1 (PD-1) immune checkpoint inhibitor. We analyzed the mutations in 113 CRCs without MSI (MSS) and 29 CRCs with MSI-High (MSI-H) using the 50-gene AmpliSeq cancer panel. Overall, MSI-H CRCs showed significantly higher mutations than MSS CRCs, including insertion/deletion mutations at repeat regions. MSI-H CRCs showed higher incidences of mutations in the BRAF, PIK3CA, and PTEN genes as well as mutations in the receptor tyrosine kinase families. While the increased mutations in BRAF and PTEN in MSI-H CRCs are well accepted, we also support findings of mutations in the mTOR pathway and receptor tyrosine kinase family genes. MSS CRCs showed higher incidences of mutations in the APC, KRAS and TP53 genes, confirming previous findings. NGS assays may be designed to detect driver mutations for targeted therapeutics and to identify tumors with high mutation loads for potential treatment with immune checkpoint blockade therapies. Further studies may be warranted to elucidate potential targeted therapeutics against mutations in the mTOR pathway and the receptor tyrosine kinase family in MSI-H CRCs as well as the benefit of anti-PD-1 immunotherapy in hypermutated MSS CRCs or other cancers.

Original languageEnglish (US)
Pages (from-to)42334-42344
Number of pages11
JournalOncotarget
Volume6
Issue number39
DOIs
StatePublished - 2015

Fingerprint

Microsatellite Instability
Colorectal Neoplasms
Mutation
Receptor Protein-Tyrosine Kinases
INDEL Mutation
APC Genes
DNA Mismatch Repair
Neoplasm Genes
Incidence
p53 Genes
Therapeutics
Tumor Burden
Immunotherapy
Genes
Neoplasms

Keywords

  • Colorectal cancer
  • Microsatellite instability
  • MTOR pathway
  • Mutation profiling
  • PTEN

ASJC Scopus subject areas

  • Oncology

Cite this

Mutational profiling of colorectal cancers with microsatellite instability. / Lin, Elaine I.; Tseng, Li Hui; Gocke, Christopher; Reil, Stacy; Le, Dung; Azad, Nilofer; Eshleman, James.

In: Oncotarget, Vol. 6, No. 39, 2015, p. 42334-42344.

Research output: Contribution to journalArticle

@article{a22a1267555f4fa9a2a8816aa993d366,
title = "Mutational profiling of colorectal cancers with microsatellite instability",
abstract = "Microsatellite instability (MSI) is caused by defective mismatch repair in 15-20{\%} of colorectal cancers (CRCs). Higher mutation loads in tumors with mismatch repair deficiency can predict response to pembrolizumab, an anti-programmed death 1 (PD-1) immune checkpoint inhibitor. We analyzed the mutations in 113 CRCs without MSI (MSS) and 29 CRCs with MSI-High (MSI-H) using the 50-gene AmpliSeq cancer panel. Overall, MSI-H CRCs showed significantly higher mutations than MSS CRCs, including insertion/deletion mutations at repeat regions. MSI-H CRCs showed higher incidences of mutations in the BRAF, PIK3CA, and PTEN genes as well as mutations in the receptor tyrosine kinase families. While the increased mutations in BRAF and PTEN in MSI-H CRCs are well accepted, we also support findings of mutations in the mTOR pathway and receptor tyrosine kinase family genes. MSS CRCs showed higher incidences of mutations in the APC, KRAS and TP53 genes, confirming previous findings. NGS assays may be designed to detect driver mutations for targeted therapeutics and to identify tumors with high mutation loads for potential treatment with immune checkpoint blockade therapies. Further studies may be warranted to elucidate potential targeted therapeutics against mutations in the mTOR pathway and the receptor tyrosine kinase family in MSI-H CRCs as well as the benefit of anti-PD-1 immunotherapy in hypermutated MSS CRCs or other cancers.",
keywords = "Colorectal cancer, Microsatellite instability, MTOR pathway, Mutation profiling, PTEN",
author = "Lin, {Elaine I.} and Tseng, {Li Hui} and Christopher Gocke and Stacy Reil and Dung Le and Nilofer Azad and James Eshleman",
year = "2015",
doi = "10.18632/oncotarget.5997",
language = "English (US)",
volume = "6",
pages = "42334--42344",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "39",

}

TY - JOUR

T1 - Mutational profiling of colorectal cancers with microsatellite instability

AU - Lin, Elaine I.

AU - Tseng, Li Hui

AU - Gocke, Christopher

AU - Reil, Stacy

AU - Le, Dung

AU - Azad, Nilofer

AU - Eshleman, James

PY - 2015

Y1 - 2015

N2 - Microsatellite instability (MSI) is caused by defective mismatch repair in 15-20% of colorectal cancers (CRCs). Higher mutation loads in tumors with mismatch repair deficiency can predict response to pembrolizumab, an anti-programmed death 1 (PD-1) immune checkpoint inhibitor. We analyzed the mutations in 113 CRCs without MSI (MSS) and 29 CRCs with MSI-High (MSI-H) using the 50-gene AmpliSeq cancer panel. Overall, MSI-H CRCs showed significantly higher mutations than MSS CRCs, including insertion/deletion mutations at repeat regions. MSI-H CRCs showed higher incidences of mutations in the BRAF, PIK3CA, and PTEN genes as well as mutations in the receptor tyrosine kinase families. While the increased mutations in BRAF and PTEN in MSI-H CRCs are well accepted, we also support findings of mutations in the mTOR pathway and receptor tyrosine kinase family genes. MSS CRCs showed higher incidences of mutations in the APC, KRAS and TP53 genes, confirming previous findings. NGS assays may be designed to detect driver mutations for targeted therapeutics and to identify tumors with high mutation loads for potential treatment with immune checkpoint blockade therapies. Further studies may be warranted to elucidate potential targeted therapeutics against mutations in the mTOR pathway and the receptor tyrosine kinase family in MSI-H CRCs as well as the benefit of anti-PD-1 immunotherapy in hypermutated MSS CRCs or other cancers.

AB - Microsatellite instability (MSI) is caused by defective mismatch repair in 15-20% of colorectal cancers (CRCs). Higher mutation loads in tumors with mismatch repair deficiency can predict response to pembrolizumab, an anti-programmed death 1 (PD-1) immune checkpoint inhibitor. We analyzed the mutations in 113 CRCs without MSI (MSS) and 29 CRCs with MSI-High (MSI-H) using the 50-gene AmpliSeq cancer panel. Overall, MSI-H CRCs showed significantly higher mutations than MSS CRCs, including insertion/deletion mutations at repeat regions. MSI-H CRCs showed higher incidences of mutations in the BRAF, PIK3CA, and PTEN genes as well as mutations in the receptor tyrosine kinase families. While the increased mutations in BRAF and PTEN in MSI-H CRCs are well accepted, we also support findings of mutations in the mTOR pathway and receptor tyrosine kinase family genes. MSS CRCs showed higher incidences of mutations in the APC, KRAS and TP53 genes, confirming previous findings. NGS assays may be designed to detect driver mutations for targeted therapeutics and to identify tumors with high mutation loads for potential treatment with immune checkpoint blockade therapies. Further studies may be warranted to elucidate potential targeted therapeutics against mutations in the mTOR pathway and the receptor tyrosine kinase family in MSI-H CRCs as well as the benefit of anti-PD-1 immunotherapy in hypermutated MSS CRCs or other cancers.

KW - Colorectal cancer

KW - Microsatellite instability

KW - MTOR pathway

KW - Mutation profiling

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=84951858024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951858024&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5997

DO - 10.18632/oncotarget.5997

M3 - Article

C2 - 26517354

AN - SCOPUS:84951858024

VL - 6

SP - 42334

EP - 42344

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 39

ER -